

To regulate blood glucose,¹⁻³ lower body weight¹⁻³ and reduce CV risk factors^{*1-5} in type 2 diabetes

GLP-1 RAs mimic
the natural GLP-1 hormonal response¹ and

BOOST
SIGNALLING
within the body^{6,7}


**A simple guide to explaining
the benefits of GLP-1 RAs**

*Reduce CV risk factors vs placebo,¹⁻⁵ including reduction in blood pressure,^{3,7} plasma triglyceride levels and body weight.⁷

This material is a DRAFT for preparatory internal use in Novo Nordisk only. Affiliates are responsible for compliance with local procedures and for review of such material, eg. against more stringent local legislation, and, if relevant, local code of conduct before distribution.

CV, cardiovascular; GLP-1, glucagon-like peptide-1; GLP-1 RAs, glucagon-like peptide-1 receptor agonists.





The effect of natural GLP-1 is reduced in type 2 diabetes⁸⁻¹⁰

The reduced effect of natural GLP-1 in type 2 diabetes impairs its ability to:

- Stimulate insulin secretion and inhibit glucagon release from the pancreas²
- Inhibit hepatic glucose production^{8,11}
- Promote satiety in the central nervous system⁶
- Delay gastric emptying²
- Reduce several cardiovascular (CV) risk factors^{*6,7}

These effects contribute to unregulated blood glucose, weight gain and increased CV risk factors^{2,6-11}

GLP-1 receptor agonists (GLP-1 RAs) mimic naturally occurring GLP-1 and boost signalling at GLP-1 receptors in multiple organs^{1,6,7,12,13}

This helps to address several defects in type 2 diabetes, whereas other agents, such as metformin, mainly target one¹⁴

*Reduce CV risk factors vs placebo,^{1,5} including reduction in blood pressure,^{3,7} plasma triglyceride levels and body weight.⁷



GLP-1 RAs help patients control their blood sugar level^{1,11,14}

- GLP-1 RAs only work in response to high blood sugar level, which is why there is a low risk of hypoglycaemia for patients^{1,14}



GLP-1 RAs can help patients lose weight^{1,2}

- GLP-1 RAs can act on the central nervous system to reduce patients' appetite and make them feel full sooner, so that they eat less^{1,12}
- GLP-1 RAs also slow food absorption by slowing emptying of food from the stomach, preventing blood sugar from spiking after a meal¹¹
- These effects are why some patients might feel nauseous to start with, but this tends to decrease with time¹¹
- Some patients may also experience other digestive issues, such as diarrhoea or constipation¹¹



GLP-1 RAs can help protect patients' heart and blood vessels^{*5}

- GLP-1 RAs can reduce patients' blood pressure and blood triglyceride levels, so that there is less burden on the heart and blood vessels^{1-4,12,13}
- These effects can also help protect the kidneys^{3,12}

Consider GLP-1 RAs for your patients to address the multiple defects of type 2 diabetes^{1,14}

*All GLP-1 RAs have been shown to reduce CV risk factors^{1-4,12,13} and some have been proven to reduce the risk of CV events.⁵


A simple way to explain the benefits of GLP-1 RAs to your patients with type 2 diabetes

Glucagon-like peptide-1 or GLP-1 is a hormone produced in the body, with a number of effects in various organs. In type 2 diabetes, these effects of GLP-1 are reduced.⁸⁻¹⁰

GLP-1 RAs or glucagon-like peptide-1 receptor agonists can mimic natural GLP-1 and boost GLP-1 signalling in multiple organs^{1,6,7,12,13}

GLP-1 receptor agonists can help you control your blood sugar level^{1,11,14}

- GLP-1 receptor agonists only work to reduce blood sugar level when it is high, which is why there is a low risk of hypoglycaemia or low blood sugar level^{1,14}





GLP-1 RAs can help you lose weight^{1,2}

- GLP-1 RAs can reduce your appetite and make you feel full sooner, so that you eat less^{1,12}
- GLP-1 RAs also slow food absorption by slowing emptying of food from the stomach¹¹
- These effects may cause you to feel nauseous to start with, but this tends to reduce with time¹¹
- You may also experience other digestive issues, such as diarrhoea or constipation¹¹



GLP-1 RAs can help protect your heart and blood vessels^{*5}

- GLP-1 RAs can reduce your blood pressure and blood triglyceride (fat) levels, so that there is less burden on your heart and blood vessels^{1-4,12,13}
- These effects can also help protect your kidneys^{3,12}

GLP-1 receptor agonists can help you control your blood sugar level, lose weight and protect your heart^{1,14}

*All GLP-1 RAs have been shown to reduce CV risk factors^{1-4,12,13} and some have been proven to reduce the risk of CV events.⁵

A large white rounded rectangle containing ten horizontal dotted lines for writing notes.



References:

1. Cornell S. *J Clin Pharm Ther.* 2020;45(Suppl 1):17–27.
2. Andreasen CR, et al. *Endocr Connect.* 2021;10(7):R200–R212.
3. Nauck MA, et al. *Mol Metab.* 2021;46:101102.
4. Andrikou E, et al. *Hellenic J Cardiol.* 2019;60(6):347–351.
5. Kristensen SL, et al. *Lancet Diabetes Endocrinol.* 2019;7(10):776–785.
6. Reed J, et al. *F1000Res.* 2020 Apr 6;9:F1000 Faculty Rev-239. doi: 10.12688/f1000research.20602.1. eCollection 2020.
7. Muskiet MHA, et al. *Nat Rev Nephrol.* 2017;13(10):605–628.
8. Sharma D, et al. *Biomed Pharmacother.* 2018;108:952–962.
9. Holst JJ, et al. *Mol Cell Endocrinol.* 2009;297(1-2):127–136.
10. Nauck MA, Meier JJ. *Lancet Diabetes Endocrinol.* 2016;4(6):525–536.
11. Shaefer Jr CF, et al. *Postgrad Med.* 2015;127(8):818–826.
12. Kalra S, et al. *Diabetes Ther.* 2019;10(5):1645–1717.
13. Sposito A, et al. *Cardiovasc Diabetol.* 2018;17(1):157.
14. Rasalam R, et al. *Diabetes Ther.* 2019;10(4):1205–1217.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.
2021 © Novo Nordisk A/S. Novo Allé, DK-2880, Bagsværd, Denmark

KW22D100005